Results indicated that SPARC modification enhanced the therapeutic effects of ADMSC by expediting corneal swelling recovery, promoting nictitating gland, corneal, and conjunctival tissue repair, enhancing tear secretion restoration, reducing inflammation in dry eye dogs, and accelerating epithelial cell proliferation in corneal tissue. This evidence concerns the gene SPARC and dry eye syndrome.